Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
129
resultados
Última actualización
24/04/2025 [07:05:00]
Resultados 50 a 75 de 129
Resumen de: US2025116625A1
An analyte sensor includes a microcontroller, a base layer, a conductive layer disposed on the base layer where the conductive layer includes a working electrode configured to provide a current signal in presence of glucose, an interference rejection membrane (“IRM”) layer disposed on the working electrode where the IRM layer is negatively charged, and an enzyme layer disposed on the IRM layer where the enzyme layer includes an enzyme selected to generate a detectable electrical signal upon exposure to the glucose. The microcontroller is configured to process an electrochemical impedance spectroscopy (EIS) parameter to determine a state of the IRM layer.
Resumen de: US2025114275A1
The present invention relates to an insulin bottle insulator and protection device. The device is comprised of a body, an interior space, and a cooling element. The device is further comprised of a lid that keeps the cold air in the device. The interior space is further comprised of an interior protection sleeve that protects the insulin bottle from breaks and cracks if dropped. The device further allows the user to be able to transport their insulin bottles without the risk of being broken or becoming unusable because they become too warm.
Resumen de: US2025114385A1
An organic glucose beverage and a novel glucose monitoring system are provided that significantly improves process of diabetes screening, diagnosis, and treatment of hypoglycemia including gestational diabetes mellitus (GDM), type-1 diabetes, type-2 diabetes, and hypoglycemia. The organic glucose beverage comprises organic glucose in form of dextrose monohydrate, juice concentrates, citric acid, and water. The organic glucose beverage is provided in the form of a ready-to-drink beverage. The glucose monitoring system comprises an organic glucose beverage, a device for blood sugar monitoring, and a device for the determination of a predefined threshold value. The present invention provides first time an organic beverage for gestational diabetes mellitus (GDM), type-1 diabetes, type-2 diabetes, and hypoglycemia. The organic glucose beverage of the present invention is healthier, well tolerated, and does not include artificial flavors, dyes, or toxic preservatives which sets it apart from conventional glucose solutions for use in diabetes screening and diagnosis.
Resumen de: AU2023280320A1
Certain aspects provide a monitoring system comprising a continuous analyte sensor configured to generate analyte measurements associated with analyte levels of a patient, and a sensor electronics module coupled to the continuous analyte sensor and configured to receive and process the analyte measurements.
Resumen de: GB2634417A
A botulinum toxin syringe having a barrel has volumetric marking graduations scaled at four units per 0.1 mL. These volumetric marking graduations allow for ease of unit conversion and can reduce the likelihood of overdosing or under dosing of botulinum toxin. The syringe may further comprise further volumetric marking graduations configured to be interchangeably used for administration of insulin or botulinum toxin. The syringe may further comprise further volumetric marking graduations configured for interchangeably use for administration of different types of botulinum toxin.
Resumen de: US2022323676A1
A computer-implemented diabetes management method includes a first determination of an insulin bolus related to one or more obtained glucose values and optionally the expected carbohydrate content of a meal to be ingested, a re-calculation of an insulin bolus in consideration of a user's body parameter information as measured by a body-worn sensor, providing a notification to the user if there is a significant deviation between the two calculated bolus amounts, and a user input whether the calculated insulin bolus or the re-calculated insulin bolus is selected by the user for bolus administration.
Resumen de: WO2025072927A1
Systems and methods are provided including insulin pump systems for determining certain information about a user of a wearable insulin pump based on naturally spoken user data by applying the user data to a large language model (LLM) or other machine learning model to parse the user data into categories. For example, certain rules and/or constraints may be provided to the LLM and may cause the LLM or machine learning model to parse the user data into defined categories that may be used for updating a user record. Categories may include food consumption, activities, sleep, and/or pump operation information, for example. Additional data may be determined from the parsed data such as caloric information, exercise duration, sleep information and the like. The parsed categorized data and/or additional data may be used to adjust operation of the insulin delivery pump.
Resumen de: WO2025068973A1
A method of non-invasive determination of the blood glucose concentration in the patient's tissue based on a radio noise signal received using an antenna brought close to the patient's skin according to the invention involves use of the radio noise signal is measured using a passive radiometer and additionally the method includes the following steps: a step of obtaining transformation coefficients, a step of measuring the temperature of the tissue surface, a step of measuring the temperatures of the active elements of the receiving chain of the radiometer, a step of measuring the currents consumed by the active elements of the receiving chain of the radiometer, a step of measuring the power of the radio noise signal originating from the tissue, and a step of determining the blood glucose concentration based on the aforementioned values. The invention also relates to a computer program, a radiometer, and a device for determining glucose concentration.
Resumen de: WO2025072005A1
An applicator may include a housing made of a uniform synthetic material. The applicator may include a sharp carrier coupled to a sharp, the sharp carrier also being made of the uniform synthetic material. The applicator may include a retraction spring that is also made of the uniform synthetic material. The applicator may include a sheath that is also made of the uniform synthetic material. The applicator may include a firing pin that is also made of the uniform synthetic material. The applicator may include a drive spring made that is also made of the uniform synthetic material. The applicator may include a puck carrier that is also made of the uniform synthetic material. The applicator may include the glucose sensor.
Resumen de: WO2025072926A1
Systems and methods are provided for managing communication with a user of an insulin pump system for improving insulin pump operation and/or a user experience relating to the insulin delivery system. The insulin pump system may analyze data from a user of a certain insulin pump and/or data from users of different insulin pumps and determine patterns relating to such use and indicative of certain user experiences. Based on the detected patterns and/or events associated with the patterns or user experiences, user messages may be proactively sent a user device and/or smart device of the user. The user messages may be designed to improve a user experience and/or prevent a negative outcome. For example, a message may be a training video, may include a reminder to adjust pump operation for a certain activity, and/or may include an alert to reorder more supplies.
Resumen de: WO2025072346A1
Embodiments disclosed herein relate to systems and methods for adapting ambulatory infusion pump systems to operate with different types of continuous glucose monitoring (CGM) sensors. Infusion pump systems as disclosed herein can include software configured to store characteristics for different types of CGM sensors and can interface with a given type of CGM sensor based on specific characteristics and requirements of the given type of sensor.
Resumen de: WO2025072338A1
Disclosed herein are systems and methods for transitioning between different CGM sensors in an infusion pump system with no loss in continuity of glucose levels between different sensor for use in closed loop diabetes therapy. Notifications can be provided to the user when a subsequent CGM sensor ought to be inserted, based on specific mechanics of the previous CGM sensor and of the anticipated subsequent CGM sensor. The system can further provide a notification when the subsequent CGM sensor is activated following the warm up period and capable of transmitting CGM data for use in the system and can prompt the user to or automatically transition the system from communicating with the previous sensor for CGM data to the subsequent sensor. Following the transition, the system may also notify the user that the previous CGM sensor can be removed from the user's body.
Resumen de: WO2025072354A1
Enclosed herein are methods and systems for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, and a smartphone or other multi-purpose consumer electronic device (i.e., remote control device). Communications among these devices can be coordinated to ensure reliable and consistent transmission of medical data.
Resumen de: US2025107728A1
The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.
Resumen de: US2025108162A1
Embodiments disclosed herein relate to systems and methods for adapting ambulatory infusion pump systems to operate with different types of continuous glucose monitoring (CGM) sensors. Infusion pump systems as disclosed herein can include software configured to store characteristics for different types of CGM sensors and can interface with a given type of CGM sensor based on specific characteristics and requirements of the given type of sensor.
Resumen de: US2025108160A1
Systems and methods are provided for managing communication with a user of an insulin pump system for improving insulin pump operation and/or a user experience relating to the insulin delivery system. The insulin pump system may analyze data from a user of a certain insulin pump and/or data from users of different insulin pumps and determine patterns relating to such use and indicative of certain user experiences. Based on the detected patterns and/or events associated with the patterns or user experiences, user messages may be proactively sent a user device and/or smart device of the user. The user messages may be designed to improve a user experience and/or prevent a negative outcome. For example, a message may be a training video, may include a reminder to adjust pump operation for a certain activity, and/or may include an alert to reorder more supplies.
Resumen de: US2025108150A1
This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.
Resumen de: US2025107729A1
Blood glucose monitoring is a difficult task that people with diabetes often have to perform on their own. Accurate and timely prediction is vital for making decisions and recommending corrective actions. Therefore, there is a need to develop effective and accurate glucose prediction methods that allow the development of safe blood glucose monitoring systems using simple and convenient devices for the patient.The present invention describes a non-invasive method and system for the prediction of glucose values, based on the estimation from variables measured with an activity wristband. The system uses variables that are not directly related to glucose to estimate and predict glucose values and generates alerts to dangerous situations of hypoglycemia and hyperglycemia.
Resumen de: US2025108165A1
Embodiments of the present disclosure relate to approaches for more efficiently measuring glucose levels using a wearable drug delivery device. In some embodiments, the wearable drug delivery device may include a needle deployment component including a cannula and an optical conduit deployable into a user, the cannula operable to deliver a liquid drug to the user. The wearable drug delivery device may further include a glucose monitor including an optical sensor, the optical sensor operable to measure a light output received via the optical conduit.
Resumen de: EP4529835A1
A method of non-invasive determination of the blood glucose concentration in the patient's tissue based on a radio noise signal received using an antenna brought close to the patient's skin according to the invention is distinguished by that the radio noise signal is received using a total power radiometer and additionally the method includes the following steps: a step of obtaining transformation coefficients, a step of measuring the temperature of the tissue surface, a step of measuring the temperatures of the active elements of the receiving chain of the radiometer, a step of measuring the currents consumed by the active elements of the receiving chain of the radiometer, a step of measuring the power of the radio noise signal originating from the tissue, and a step of determining the blood glucose concentration based on the aforementioned values. The invention also relates to a computer program, a radiometer, and a device for determining glucose concentration.
Resumen de: EP4531051A1
Embodiments disclosed herein relate to systems and methods for adapting ambulatory infusion pump systems to operate with different types of continuous glucose monitoring (CGM) sensors. Infusion pump systems as disclosed herein can include software configured to store characteristics for different types of CGM sensors and can interface with a given type of CGM sensor based on specific characteristics and requirements of the given type of sensor.
Resumen de: GB2634100A
An inserter device 100 for securing a sensor module 101, e.g. a blood glucose monitor, to the skin 401 of a user comprises a body 107 housing a carriage (104, fig 1) for receiving the sensor module 101 and a collar 103 radially surrounding the carriage 104 and movable relative to the body 107 in an axial direction from a first position (fig 5a) to a second position (fig 5c). The collar 103 comprises one or more engagement members 103a to configured to engage one or more corresponding abutment surfaces 107a on an inner surface of the body 107 in the first position and thereby prevent relative movement of the collar and the body. The one or more engagement members 103a and/or abutment surfaces 107a are configured such that an axial force 402 applied to the body 107 causes the one or more engagement members 103a and abutment surfaces 107a to disengage from one another, thereby facilitating movement 501 of the collar from the first position to the second position, to drive a pointed end (105, fig 1) of the sensor module 101 at least partially into the skin 401 of the user.
Resumen de: EP4529936A2
Embodiments of the present disclosure are directed to miniature insulin patch pump, assistance devices (e.g., for reservoir filling and /or cannula insertion), and methods related thereto. For example, in some embodiments, a substance/drug-delivery patch pump is provided and includes a reusable part (RP) including a power source, a driving mechanism, and an electronic module, and a disposable part (DP), where the disposable part can include at least a plurality of an adhesive base, a reservoir, a dosing mechanism, and a cannula.
Resumen de: CN106456063A
The present disclosure relates to a system and method for determining a basal rate adjustment based on risk associated with a glucose state of a person with diabetes. The method may include detecting a glucose state of the person based on a received glucose measurement signal and determining a current risk metric associated with the detected glucose state. The method may include identifying a reference glucose state and a reference risk metric associated with the reference glucose state, and calculating an adjustment to a basal rate of a therapy delivery device based on the current risk metric associated with the detected glucose state and the reference risk metric associated with the reference glucose level.
Nº publicación: WO2025059863A1 27/03/2025
Solicitante:
MEDTRUM TECH INC [CN]
\u4E0A\u6D77\u79FB\u5B87\u79D1\u6280\u6709\u9650\u516C\u53F8
Resumen de: WO2025059863A1
A control system for blood glucose monitoring and management. A first working mode of the control system is to control a blood glucose monitoring device to perform real-time blood glucose monitoring. The control system enters a second working mode on the basis of a trigger condition, and the second working mode at least comprises controlling the blood glucose monitoring device to perform real-time blood glucose monitoring and controlling an insulin infusion device to perform insulin infusion. By means of the trigger condition, the control system enters the second working mode of at least controlling the blood glucose monitoring device to perform real-time blood glucose monitoring and controlling the insulin infusion device to perform insulin infusion from the first working mode of controlling the blood glucose monitoring device to perform real-time blood glucose monitoring, so that a patient is prevented from accidentally entering unnecessary or unauthorized working modes, and the safety of blood glucose monitoring and management of the patient is improved.
BOPI
Sede Electrónica
